Marker Therapeutics Inc (MRKR)

[lasers]

TapImmune, Inc. Presentation Now Available for On-Demand Viewing
PR NEWSWIRE 4:05 PM ET 12/11/2017
Symbol Last Price Change
TPIV 3.11up +0.04 (+1.3%)
QUOTES AS OF 04:00:00 PM ET 12/11/2017
Company invites individual and institutional investors to view presentation at VirtualInvestorConferences.com

JACKSONVILLE, Fla. , Dec. 11, 2017 /PRNewswire/ -- TapImmune Inc.(TPIV) , a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that Peter Hoang, President and Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.

LINK: https://tinyurl.com/1207postpr

TapImmune's (TPIV) presentation will be available for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

Recent Company Highlights

Potential to be a dominant player in T-cell cancer vaccines by eliciting both helper and killer T-cell responses; durable immune response generated by >90% of vaccinated patients against target
Evaluating lead candidate in four ongoing Phase 2 studies in ovarian cancer and triple-negative breast cancer; additional studies planned for HER2+ breast cancer vaccine
Capital efficient clinical strategy: two studies fully funded by grants totaling approx. $17 million
PolyStart™ antigen expression technology offers multiple out-licensing opportunities
Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Department of Defense